SCHEMBL13718948

SCHEMBL13718948

Cc1ccc(Oc2cccc(CC(C)C)c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 1/20 0.48
▸ TAAR1 Q96RJ0 2/20 0.47
▸ HTT P42858 2/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ MMP13 P45452 1/20 0.46
▸ CETP P11597 3/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ PPARG P37231 1/20 0.44
▸ PPARA Q07869 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ FDFT1 P37268 2/20 0.43
▸ FAAH O00519 1/20 0.42
▸ DRD2 P14416 1/20 0.42
▸ PTGES O14684 1/20 0.42
▸ MME P08473 1/20 0.41
▸ ACE P12821 1/20 0.41
▸ CPA1 P15085 1/20 0.41
▸ ACE2 Q9BYF1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9538055 0.89 TAAR1 (0.56) FFAR1TAAR1HTTTDP1CETP
SCHEMBL8174800 0.88 CETP (0.54) FFAR1TAAR1HTTTDP1CETP
SCHEMBL13718930 0.87 TAAR1 (0.60) TAAR1HTTCETPALDH1A1PPARG
SCHEMBL8171976 0.85 CETP (0.47) TAAR1HTTCETPALDH1A1PPARG
SCHEMBL13719088 0.85 PPARG (0.59) TAAR1HTTCETPALDH1A1PPARG
SCHEMBL13719346 0.83 FDFT1 (0.50) TAAR1HTTCETPALDH1A1PPARG
SCHEMBL13719538 0.82 TEAD4 (0.48) TDP1ALDH1A1PPARGPPARA
SCHEMBL8243884 0.81 FFAR1 (0.51) FFAR1HTTTDP1L3MBTL1MMP13
SCHEMBL13719216 0.81 KMO (0.48) TAAR1CETPALDH1A1PPARGPPARA
SCHEMBL8172098 0.81 FDFT1 (0.47) TAAR1HTTCETPALDH1A1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579479-B2 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method BRISTOL-MYERS SQUIBB COMPANY (US) 2009-08-25 — — US disclosed
US-7241780-B2 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method BRISTOLS-MYERS SQUIBB COMPANY (US) 2007-07-10 — — US disclosed
US-20070015797-A1 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method CHENG PETER T 2007-01-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015797-A1 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method GPR119, LIPC, ACACA FFAR1 28/4885TAAR1 2294/4885HTT 2959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback